(Q45415883)

14 December 2017

title

Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. (English)

1 reference

14 December 2017

vaccinia virus

1 reference

Charani Ranasinghe

1

1 reference

14 December 2017

Jill C Medveczky

2

1 reference

14 December 2017

Donna Woltring

3

1 reference

14 December 2017

Ke Gao

4

1 reference

14 December 2017

Scott Thomson

5

1 reference

14 December 2017

Barbara E H Coupar

6

1 reference

14 December 2017

David B Boyle

7

1 reference

14 December 2017

Alistair J Ramsay

8

1 reference

14 December 2017

Ian A Ramshaw

9

1 reference

14 December 2017

language of work or name

English

0 references

publication date

2 May 2006

1 reference

14 December 2017

1 reference

14 December 2017

volume

24

1 reference

14 December 2017

issue

31-32

1 reference

14 December 2017

page(s)

5881-5895

1 reference

Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

The prime-boost strategy: exciting prospects for improved vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Impairment of Gag-specific CD8(+) T-cell function in mucosal and systemic compartments of simian immunodeficiency virus mac251- and simian-human immunodeficiency virus KU2-infected macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

The Role of Mucosal Immunity in Prevention of HIV Transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Mucosal HIV vaccines: where are we now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Mucosal AIDS vaccines: current status and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Vaccination strategies for mucosal immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

DNA immunization via intramuscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Heterologous priming-boosting immunization of cattle with Mycobacterium tuberculosis 85A induces antigen-specific T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

The induction of HIV Gag-specific CD8+ T cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with recombinant Listeria monocytogenes HIV Gag.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

HIV-1 DNA vaccines and chemokines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Cytokine, Chemokine, and Costimulatory Molecule Modulation to Enhance Efficacy of HIV Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Multiple-cloning-site plasmids for the rapid construction of recombinant poxviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Vaccination against Fowlpox virus via drinking water.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Reversal in the immunodominance hierarchy in secondary CD8+ T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodomination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

T cells down-modulate peptide-MHC complexes on APCs in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN? or IL-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.04.023

10.1016/J.VACCINE.2006.04.023

7 January 2021

Identifiers

DOI

1 reference

14 December 2017

1 reference